Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m2 PEG asparaginase in children with ALL treated according to protocol COALL-06-97

Pediatric Blood and Cancer

Volumn 46, Issue 1, 2006, Pages 18-25

  Pinheiro, J P Vieira ^a   Wenner, K ^b   Escherich, G ^b   Lanvers Kaminsky, C ^a   Wurthwein G ^a   Janka Schaub, G ^b   Boos, J ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Acute lymphoblastic leukaemia; Asparaginase; Asparagine; Children; CSF

Indexed keywords

ASPARAGINASE; ASPARAGINASE MACROGOL; ASPARAGINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; TENIPOSIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CEREBROSPINAL FLUID; CHILD; CLINICAL PROTOCOL; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG MONITORING; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; BIOLOGICAL AVAILABILITY; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; POLYETHYLENE GLYCOLS;

EID: 28844458850     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20406     Document Type: Article

References (42)

1. Muller HJ, Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol 1998;28:97-113.
2. Ettinger LJ, Ettinger AG, Avramis VI, et al. Acute lymphoblastic leukaemia: A guide to asparaginase and pegaspargase therapy. Bio Drugs 1997;7:30-39.
3. Keating MJ, Holmes R, Lerner S, et al. L-asparaginase and PEG asparaginase-Past, present, and future. Leuk Lymphoma 1993;10:153-157.
4. Cooney DA, Handschumacher RE. L-asparaginase and L-asparagine metabolism. Annu Rev Pharmacol 1970;10:421-440.
5. Prager MD, Bachynsky N. Asparagine synthetase in normal and malignant tissues: Correlation with tumor sensitivity to asparaginase. Arch Biochem Biophys 1968;127:645-654.
6. Haley EE, Fischer GA, Welch AD. The requirement for L-asparagine of mouse leukemia cells L5178Yin culture. Cancer Res 1961;21:532-536.
7. Oettgen HF, Stephenson PA, Schwartz MK, et al. Toxicity of E. coli L-asparaginase in man. Cancer 1970;25:253-278.
8. Killander D, Dohlwitz A, Engstedt L, et al. Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer 1976;37:220-228.
9. Evans WE, Tsiatis A, Rivera G, et al. Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer 1982;49:1378-1383.
10. Kurtzberg J, Asselin B, Poplack D, et al. Antibodies to asparaginase alter pharmacokinetics and decrease enzyme activity in patients on asparaginase therapy. Proc Am Assoc Cancer Res 1993;34:304.
11. Kurtzberg J. A new look at PEG-L-asparaginase and other asparaginases in hematological malignancies. Cancer Investigation 1994;12:59-60.
12. Kamisaki Y, Wada H, Yagura T, et al. Reduction in immunogenicity and clearance rate of Escherichia coli L-asparaginase by modification with monomethoxypolyethylene glycol. J Pharmacol Exp Ther 1981;216:410-414.
13. Schellekens H. Immunogenicity of therapeutic proteins: Clinical implications and future prospects. Clin Ther 2002;24:1720-1740.
14. Ho DH, Brown NS, Yen A, et al. Clinical pharmacology of polyethylene glycol-L-asparaginase. Drug Metab Dispos 1986;14:349-352.
15. Asselin BL, Whitin JC, Coppola DJ, et al. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993;11:1780-1786.
16. Boos J, Werber G, Ahlke E, et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer 1996;32A:1544-1550.
17. Ahlke E, Nowak-Gottl U, Schulze-Westhoff P, et al. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. Br J Haematol 1997;96:675-681.
18. Vieira Pinheiro JP, Ahlke E, Nowak-Gottl U, et al. Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols. Br J Haematol 1999;104:313-320.
19. Muller HJ, Loning L, Horn A, et al. Pegylated asparaginase (Oncaspar) in children with ALL: Drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br J Haematol 2000;110:379-384.
20. Rizzari C, Zucchetti M, Conter V, et al. L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure. Ann Oncol 2000;11:189-193.
21. Albertsen BK, Schroder H, Ingerslev J, et al. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: Pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system. Br J Haematol 2001;115:983-990.
22. Albertsen BK, Schroder H, Jakobsen P, et al. Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries. Br J Clin Pharmacol 2001;52:433-437.
23. Muller HJ, Beier R, Loning L, et al. Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. Br J Haematol 2001;114:794-799.
24. Vieira Pinheiro JP, Muller HJ, Schwabe D, et al. Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia. Br J Haematol 2001;113:115-119.
25. Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: A Children's Cancer Group study. Blood 2002;99:1986-1994.
26. Muller HJ, Beier R, da Palma JC, et al. PEG-asparaginase (Oncaspar) 2500 U/m(2) BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols. Cancer Chemother Pharmacol 2002;49:149-154.
27. Asselin BL, Lorenson MY, Whitin JC, et al. Measurement of serum L-asparagine in the presence of L-asparaginase requires the presence of an L-asparaginase inhibitor. Cancer Res 1991;51:6568-6573.
28. Schwartz MK, Lash ED, Oettgen HF, et al. L-asparaginase activity in plasma and other biological fluids. Cancer 1970;25:244-252.
29. Riccardi R, Holcenberg JS, Glaubiger DL, et al. L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res 1981;41:4554-4558.
30. Harms DO, Janka-Schaub GE. Co-operative study group for childhood acute lymphoblastic leukemia (COALL): Long-term follow-up of trials 82, 85, 89 and 92. Leukemia 2000;14:2234-2239.
31. Lanvers C, Vieira Pinheiro JP, Hempel G, et al. Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum. Anal Biochem 2002;309:117-126.
32. Lenda K, Svenneby G. Rapid high-performance liquid chromatographic determination of amino acids in synaptosomal extracts. J Chromatogr 1980;198:516-519.
33. Abshire TC, Pollock BH, Billett AL, et al. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: A Pediatric Oncology Group Study. Blood 2000;96:1709-1715.
34. Vilmer E, Suciu S, Ferster A, et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: A CLCG-EORTC report. Children Leukemia Cooperative Group. Leukemia 2000;14:2257-2266.
35. Duval M, Suciu S, Ferster A, et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: Results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood 2002;99:2734-2739.
36. Gerrits GP, Trijbels FJ, Monnens LA, et al. Reference values for amino acids in cerebrospinal fluid of children determined using ion-exchange chromatography with fluorimetric detection. Clin Chim Acta 1989;182:271-280.
37. Woo MH, Hak LJ, Storm MC, et al. Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia. J Clin Oncol 1999;17:1568-1573.
38. Ohnuma T, Holland JF, Freeman A, et al. Biochemical and pharmacological studies with asparaginase in man. Cancer Res 1970;30:2297-2305.
39. Gentili D, Conter V, Rizzari C, et al. L-Asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase. Ann Oncol 1996;7:725-730.
40. Hawkins DS, Park JR, Thomson BG, et al. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. Clin Cancer Res 2004;10:5335-5341.
41. Appel IM, Pinheiro JP, den Boer ML, et al. Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: A window study at initial diagnosis of childhood ALL. Leukemia 2003;17:2254-2256.
42. Broome JD. Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. II. Lymphoma 6C3HED cells cultured in a medium devoid of L-asparagine lose their susceptibility to the effects of guinea pig serum in vivo. J Exp Med 1963;118:121-148.